Payment overview · 2025
General Payments
$2,885.89
185 reported records · 21 companies
Healthcare provider profile · identity verified
Raymond Candelaria
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · KOKOMO, IN · NPI 1023775848
Verified facts
What the public records show
CMS Open Payments records show Raymond Candelaria received $2,885.89 in general payments during 2025 across 185 reported records.
PFIZER INC. accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $506.60 | 17.6% | 31 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $422.08 | 14.6% | 38 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $320.54 | 11.1% | 26 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $296.48 | 10.3% | 17 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $260.93 | 9.0% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $194.92 | 6.8% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $184.64 | 6.4% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $158.42 | 5.5% | 14 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $90.73 | 3.1% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $90.33 | 3.1% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $89.98 | 3.1% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $58.40 | 2.0% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $49.59 | 1.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.76 | 1.1% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.27 | 1.0% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $19.90 | 0.7% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.99 | 0.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $18.13 | 0.6% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $15.06 | 0.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.31 | 0.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $13.83 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,885.89 | 185 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $420.03 | 24 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $395.24 | 23 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $386.81 | 21 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $260.93 | 12 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $260.93 | 12 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $238.54 | 21 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $173.82 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $173.82 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $161.33 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $160.06 | 16 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $158.42 | 14 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $156.99 | 15 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $139.66 | 14 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $132.43 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $111.04 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $90.73 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $89.98 | 4 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $73.89 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $58.40 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $55.29 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $49.59 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $32.76 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $29.27 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $21.10 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $12.68 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $12.68 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $12.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 183 | 52 |
| Atorvastatin Calcium | Atorvastatin Calcium | 171 | 53 |
| Alprazolam | Alprazolam | 140 | 24 |
| Prednisone | Prednisone | 139 | 116 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 133 | 51 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 113 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 99 | 32 |
| Pregabalin | Pregabalin | 91 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 75 | 25 |
| Tramadol Hcl | Tramadol Hcl | 73 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 67 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 11 |
| Levothyroxine Sodium | Levothyroxine Sodium | 57 | 21 |
| Methocarbamol | Methocarbamol | 56 | 12 |
| Mounjaro | Tirzepatide | 56 | suppressed |
| Omeprazole | Omeprazole | 54 | 18 |
| Sertraline Hcl | Sertraline Hcl | 54 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 42 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 14 |
| Mirtazapine | Mirtazapine | 45 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | suppressed |
| Furosemide | Furosemide | 42 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 41 | 18 |
| Meloxicam | Meloxicam | 39 | 12 |
| Potassium Chloride | Potassium Chloride | 39 | 11 |
| Diazepam | Diazepam | 38 | suppressed |
| Lisinopril | Lisinopril | 38 | 17 |
| Donepezil Hcl | Donepezil Hcl | 37 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 22 |
| Metformin Hcl | Metformin Hcl | 35 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 32 |
| Ondansetron Odt | Ondansetron | 33 | 16 |
| Celecoxib | Celecoxib | 32 | 13 |
| Dexamethasone | Dexamethasone | 32 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | 13 |
| Temazepam | Temazepam | 30 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | 11 |
| Eliquis | Apixaban | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 26 | 13 |
| Trazodone Hcl | Trazodone Hcl | 26 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Losartan Potassium | Losartan Potassium | 22 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 19 |
| Amoxicillin | Amoxicillin | 19 | 16 |
| Azithromycin | Azithromycin | 19 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Simvastatin | Simvastatin | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Armodafinil | Armodafinil | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Olanzapine Odt | Olanzapine | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Ativan | Lorazepam | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Carvedilol | Carvedilol | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,885.89 · 185 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AUSTEDO XR, Auvelity, CAPLYTA, COMIRNATY, CREON, EVENITY, FANAPT, FARXIGA, HETLIOZ, INGREZZA, JARDIANCE, KISUNLA, Kerendia, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, Qelbree, REXULTI, Rybelsus, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XYOSTED, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error